Last reviewed · How we verify
Janthinobacterium lividum
At a glance
| Generic name | Janthinobacterium lividum |
|---|---|
| Sponsor | DermBiont, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis (PHASE2)
- Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Janthinobacterium lividum CI brief — competitive landscape report
- Janthinobacterium lividum updates RSS · CI watch RSS
- DermBiont, Inc. portfolio CI